Smith-Farrell will lead the next phase of growth as Orbis evolves its platform, advances its pipeline, and builds on its collaboration with Novo Nordisk, valued at up to $1.4 billion Co-founder Morten Graugaard becomes Chief Business Officer, leading business development amid strong partnering momentum COPENHAGEN, October 27, 2026--(BUSINESS WIRE)--Orbis Medicines, a leader in the discovery of next-generation macrocycles, oral medicines with biologics-like potency, today announced the appointment of Joanne Smith-Farrell, Ph.D., as Chief Executive Officer. She succeeds co-founder Morten Graugaard, who becomes Chief Business Officer. Dr.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.